{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T04:54:33Z","timestamp":1744692873535},"reference-count":42,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutics and Clinical Risk Management"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.2147\/tcrm.2006.2.3.297","type":"journal-article","created":{"date-parts":[[2006,9,6]],"date-time":"2006-09-06T04:33:17Z","timestamp":1157517197000},"page":"297-301","source":"Crossref","is-referenced-by-count":10,"title":["Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease"],"prefix":"10.2147","volume":"2","author":[{"given":"Steven","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","reference":[{"key":"p_1_242","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00755.x"},{"key":"p_2_243","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","volume":"35","author":"Baker LR","year":"1989","journal-title":"Kidney Int"},{"key":"p_3_244","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20011629"},{"key":"p_4_245","doi-asserted-by":"publisher","DOI":"10.1007\/s004410051353"},{"key":"p_5_246","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.4049\/jimmunol.167.9.4974","volume":"167","author":"Boonstra A","year":"2001","journal-title":"J Immunol"},{"key":"p_6_247","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.5.829"},{"key":"p_7_248","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2002.122819"},{"key":"p_8_249","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1053\/ajkd.1998.v32.pm9808144","volume":"32","author":"Cato","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"p_9_250","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.01.012"},{"key":"p_10_251","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.10.007"},{"key":"p_11_252","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.36899"},{"key":"p_12_253","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh123"},{"key":"p_13_254","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2002.5474"},{"key":"p_14_255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/ajkd.1998.v32.pm9808140","volume":"32","author":"Dusso AS","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"p_15_256","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422003"},{"key":"p_16_257","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00895.x"},{"key":"p_17_258","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","volume":"310","author":"Hamdy N","year":"1995","journal-title":"BMJ"},{"key":"p_18_259","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004070610"},{"key":"p_19_260","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00651.x"},{"key":"p_20_261","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00562.x"},{"key":"p_21_262","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","volume":"38","author":"Llach F","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"p_22_263","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1053\/ajkd.2001.28112","volume":"38","author":"Martin KJ.","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"p_23_264","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","volume":"9","author":"Martin KJ","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"p_24_265","doi-asserted-by":"crossref","unstructured":"Martin KJ, Gonzalez EA, Gellens ME, etal 1998b. Therapy of secondary hyperparathyroidism with 19-nor-1alpha, 25-dihydroxyvitamin D2. Am J Kidney Dis, 32(2 Suppl 2):S61-6.","DOI":"10.1053\/ajkd.1998.v32.pm9808145"},{"key":"p_25_266","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/ki.1982.227","volume":"22","author":"McCarron DA","year":"1982","journal-title":"Kidney Int"},{"key":"p_26_267","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1677\/jme.0.0160183","volume":"16","author":"Mee A","year":"1996","journal-title":"J Mol Endocrinol"},{"key":"p_27_268","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1210\/jcem-67-5-929","volume":"67","author":"Nordal KP","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"p_28_269","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem-67-5-876","volume":"67","author":"Pitts TO","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"p_29_270","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.62.s82.15.x"},{"key":"p_30_271","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/ndt\/6.3.162","volume":"6","author":"Reichel H","year":"1991","journal-title":"Nephrol Dial Transplant"},{"key":"p_31_272","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1210\/endo-119-6-2864","volume":"119","author":"Russell J","year":"1986","journal-title":"Endocrinology"},{"key":"p_32_273","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi236"},{"key":"p_33_274","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1172\/JCI112714","volume":"78","author":"Silver J","year":"1986","journal-title":"J Clin Invest"},{"key":"p_34_275","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI111639","volume":"74","author":"Slatopolsky E","year":"1984","journal-title":"J Clin Invest"},{"key":"p_35_276","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","volume":"38","author":"Sprague SM.","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"p_36_277","doi-asserted-by":"crossref","first-page":"454","DOI":"10.5414\/CNP63454","volume":"63","author":"Staniforth M","year":"2005","journal-title":"Clin Nephrol"},{"key":"p_37_278","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.4049\/jimmunol.168.3.1181","volume":"168","author":"Staeva-Vieira T","year":"2002","journal-title":"J Immunol"},{"key":"p_38_279","unstructured":"Tan X, Liu Y. 2005. Paricalcitol attenuates renal interstitial fibrosis in mouse models of obstructive nephropathy [poster]. The Annual Meeting of the American Society of Nephrology, 11-14 November, Philadelphia, PA, USA. FPO422"},{"key":"p_39_280","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022536"},{"key":"p_40_281","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004070573"},{"key":"p_41_282","first-page":"1237","volume":"44","author":"Virdi AS","year":"1998","journal-title":"Cell Mo Biol"},{"key":"p_42_283","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1681\/ASN.V13196","volume":"13","author":"Yang J","year":"2002","journal-title":"J Am Soc Nephrol"}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T03:30:06Z","timestamp":1627788606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/oral-paricalcitol-for-the-treatment-of-secondary-hyperparathyroidism-i-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.2147\/tcrm.2006.2.3.297"],"URL":"https:\/\/doi.org\/10.2147\/tcrm.2006.2.3.297","relation":{},"ISSN":["1176-6336"],"issn-type":[{"value":"1176-6336","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}